Deep Dive: Deep Dive Into Leveraging Insurance Costs

With several high-cost specialty drugs and gene therapies in the FDA approval pipeline, employers must take steps to prepare for the potential cost burden in their employee benefit spending. Katie Asch, a US consulting pharmacy practice lead, joins Deep Dive to discuss strategies and models that employers can leverage to manage these costs, as well as other opportunities that can ensure employees and their families are paired with the right therapy.